Foghorn Therapeutics Inc.

Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update

- Advancing a novel oral small molecule in inflammatory bowel disease (IBD), with potential first-in-human trials targeted by end of 2027